Provectus Biopharmaceuticals, Inc.'s data featured in a presentation during the European Society For Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, show PV-10 has a higher rate of response in injected tumors through its ablative effect, and that the durability of response as well as the bystander response in uninjected tumors implicate an additional immunologic mechanism secondary to ablation.

The highlighted poster, presented by Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University, based upon abstract #1120P, was entitled, “Subgroup Efficacy in Patients Receiving Intralesional Rose Bengal to All Existing Melanoma in Phase II Study PV-10-MM-02.”

“Although the primary ablative effect of PV-10 can lead to rapid regression of injected lesions, durability of response may signal the effects of an immunologic process secondary to ablation. In addition to offering the potential to relieve symptoms of cutaneous melanoma, a robust, tumor-specific immunologic response could have the potential of changing the course of the disease," Dr. Agarwala said.

Eric Wachter, PhD and Chief Technology Officer of Provectus, said, "We are very pleased to share the patient-level PFS data at ESMO that defined our design parameters for the upcoming phase 3 trial. These study results demonstrate the potential of an intralesional approach to delay progression while alleviating symptoms of locally advanced melanoma.”

To learn more go to: www.pvct.com or www.clinicaltrials.gov.